Michael Cecchini

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 31

Top Topics

Benign Prostatic Hyperplasia

Metastatic Colorectal Cancer

Top Venues

British journal of cancer

NPJ precision oncology

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliot, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliott, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliott, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliott, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliott, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliot, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliot, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Sunkyu Kim, Seung-Seob Kim, Eejung Kim, Michael Cecchini, Mi-Suk Park, Ji A Choi, Sung Hyun Kim, Ho Kyoung Hwang, Chang Moo Kang, Hye Jin Choi, Sang Joon Shin, Jaewoo Kang, Choong-Kun Lee
Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer. JCO clinical cancer informatics 8 (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliott, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew Elliott, Peter Enzinger, Harshabad Singh, Jessalyn Ubellaker, Jean-Bernard Lazaro, James M Cleary, Zoltan Szallasi, Nilay S Sethi
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ precision oncology 8 (1) (2024)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward J Kim, Stacey Stein, Jeremy S Kortmansky, Sandra Canosa, Jeffrey Sklar, Elizabeth M Swisher, Marc Radke, Percy Ivy, Scott Boerner, Diane E Durecki, Chih-Yuan Hsu, Patricia LoRusso, Jill Lacy
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British journal of cancer 130 (3) (2023)
Maitri Kalra, Elizabeth Henry, Kelly E McCann, Meghan S Karuturi, Jean G Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S Mougalian, Gregory Durm, Angel Qin, Caitlin A Schonewolf, Meghna S Trivedi, Avan J Armaghani, Frederick H Wilson, Wade T Iams, Anita A Turk, Praveen Vikas, Michael Cecchini, Sam Lubner, Priyadarshini Pathak, Kristen Spencer, Vadim S Koshkin, Matthew Kyle Labriola, Catherine Handy Marshall, Kathryn E Beckermann, null null, Marina N Sharifi, Anthony C Bejjani, Varsha Hotchandani, Samir Housri, Nadine Housri
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR cancer 8 (2) (2022)
Michael Cecchini, Jeremy S Kortmansky, Can Cui, Wei Wei, Jaykumar Ranchobdhai Thumar, Nataliya V Uboha, Navid Hafez, Jill Lacy, Neal A Fischbach, Kert D Sabbath, Christina M Gomez, Jonathan Reed Sporn, Stacey Stein, Howard S Hochster
A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 127 (9) (2020)
Timil H Patel, Michael Cecchini
Targeted Therapies in Advanced Gastric Cancer. Current treatment options in oncology 21 (9) (2020)
Michael Cecchini, Eric H Rubin, Gideon M Blumenthal, Kassa Ayalew, Howard A Burris, Michele Russell-Einhorn, Hildy Dillon, Herbert Kim Lyerly, Gregory H Reaman, Scott Boerner, Patricia M LoRusso
Challenges with Novel Clinical Trial Designs: Master Protocols. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (7) (2019)